Changes of tear lipid mediators after eyelid warming or thermopulsation treatment for meibomian gland dysfunction

Ambaw, Yohannes Abere; Fuchs, David; Raida, Manfred; Mazengia, Nebyat Tadlo; Torta, Federico; Wheelock, Craig E.; Wenk, Markus R.; Tong, Louis

doi:10.1016/j.prostaglandins.2020.106474

Cited by 21 publications

(19 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2018; Ambaw et al. 2020). Despite similar diagnosis methods to recruit DED patients, the included studies described number of inclusion criteria with large heterogeneity concerning ocular surface testing and severity scales, which might have affected precision of the results.…”

Section: Discussionmentioning

confidence: 99%

Oxidative and antioxidative stress markers in dry eye disease: A systematic review and meta‐analysis

Navel

Sapin

Henrioux

et al. 2021

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose To conduct a systematic review and meta‐analysis on the levels of oxidative stress markers and antioxidants in dry eye disease (DED) compared with healthy subject. Method The PubMed, Cochrane Library, Embase, Science Direct and Google Scholar databases were searched on 10 January 2021 for studies reporting oxidative and antioxidative stress markers in DED and healthy controls. Main meta‐analysis was stratified by type of biomarkers, type of samples (tears, conjunctival cells or biopsies), Sjögren’s syndrome (SS) (patients with or without SS) and by geographical zones (Asia or Europe). Results We included nine articles, for a total of 333 patients (628 eye samples) with DED and 165 healthy controls (451 eye samples). There is an overall increase in oxidative stress markers in DED compared with healthy controls (standard mean deviation = 2.39, 95% confidence interval 1.85–2.94), with a significant increase in lipid peroxide (1.90, 0.69–3.11), myeloperoxidase (2.17, 1.06–3.28), nitric oxide synthase 3 (2.52, 0.95–4.08), xanthine oxidase/oxidoreductase (2.41, 1.40–5.43), 4‐hydroxy‐2‐nonenal (4HNE) (4.75, 1.67–7.84), malondialdehyde (3.00, 2.55–3.45) and reactive oxygen species (1.31, 0.94–1.68). Oxidative stress markers were higher in tears, conjunctival cells and conjunctival biopsies of DED than controls. Even if small number of studies were included for antioxidants, catalase seemed to be decreased in DED compared with healthy controls (−2.17, −3.00 to −1.34), with an increase of antioxidants in tears of DED patients without SS (1.13, 0.76–1.49). Conclusion Oxidative stress markers, and probably antioxidants, were dysregulated in DED, establishing a local oxidative environment in tears, conjunctival cells and tissues.

show abstract

Section: Discussionmentioning

confidence: 99%

Oxidative and antioxidative stress markers in dry eye disease: A systematic review and meta‐analysis

Navel

Sapin

Henrioux

et al. 2021

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…The use of the Strata-X for eicosanoid extraction was performed according to an earlier method with some modifications [ 26 , 34 , 35 ]. After enrichment, the eluted compounds were dried completely using a SpeedVac concentrator.…”

Section: Methodsmentioning

confidence: 99%

Tailored Polymer-Based Selective Extraction of Lipid Mediators from Biological Samples

et al. 2021

Self Cite

View full text Add to dashboard Cite

Lipid mediators, small molecules involved in regulating inflammation and its resolution, are a class of lipids of wide interest as their levels in blood and tissues may be used to monitor health and disease states or the effect of new treatments. These molecules are present at low levels in biological samples, and an enrichment step is often needed for their detection. We describe a rapid and selective method that uses new low-cost molecularly imprinted (MIP) and non-imprinted (NIP) polymeric sorbents for the extraction of lipid mediators from plasma and tissue samples. The extraction process was carried out in solid-phase extraction (SPE) cartridges, manually packed with the sorbents. After extraction, lipid mediators were quantified by liquid chromatography–tandem mass spectrometry (LC–MSMS). Various parameters affecting the extraction efficiency were evaluated to achieve optimal recovery and to reduce non-specific interactions. Preliminary tests showed that MIPs, designed using the prostaglandin biosynthetic precursor arachidonic acid, could effectively enrich prostaglandins and structurally related molecules. However, for other lipid mediators, MIP and NIP displayed comparable recoveries. Under optimized conditions, the recoveries of synthetic standards ranged from 62% to 100%. This new extraction method was applied to the determination of the lipid mediators concentration in human plasma and mouse tissues and compared to other methods based on commercially available cartridges. In general, the methods showed comparable performances. In terms of structural specificity, our newly synthesized materials accomplished better retention of prostaglandins (PGs), hydroxydocosahexaenoic acid (HDoHE), HEPE, hydroxyeicosatetraenoic acids (HETE), hydroxyeicosatrienoic acid (HETrE), and PUFA compounds, while the commercially available Strata-X showed a higher recovery for dihydroxyeicosatetraenoic acid (diHETrEs). In summary, our results suggest that this new material can be successfully implemented for the extraction of lipid mediators from biological samples.

show abstract

“…Beyond antibiotics and CsA, various office-based procedures have been evaluated in the treatment of MGD including intense pulse light, thermopulsation treatments (Lipiflow) and meibomian gland probing. [77][78][79] Each of these approaches are supported by studies that show improvement in symptoms and signs of disease, but more solid randomised control studies or studies that use patients who are resistant to ATs are limited with respect to these newer modalities. However, if ATs are not adequate, some patients with MGD may benefit from treatment escalation, such as antibiotics, anti-inflammatories and office-based procedures.…”

Section: Meibomian Gland Dysfunctionmentioning

confidence: 99%

Dry eye: why artificial tears are not always the answer

et al. 2021

View full text Add to dashboard Cite

Dry eye disease (DED) is a multifactorial disease that manifests in patients with a variety of symptoms and signs such as ocular pain, visual issues, rapid tear evaporation and/or decreased tear production. It is a global health problem and is the leading cause of optometry and ophthalmology clinic visits. The mainstay therapy for DED is artificial tears (ATs), which mimics tears and improves tear stability and properties. ATs have been found to improve symptoms and signs of disease in all DED subtypes, including aqueous deficient DED and evaporative DED. However, given the heterogeneity of DED, it is not surprising that ATs are not effective in all patients. When AT fails to relieve symptoms and/or signs of DED, it is critical to identify the underlying contributors to disease and escalate therapy appropriately. This includes underlying systemic diseases, meibomian gland dysfunction, anatomical abnormalities and neuropathic dysfunction. Thus, this review will discuss the benefits and limitations of ATs and review conditions when escalation of therapy should be considered in DED.

show abstract

Changes of tear lipid mediators after eyelid warming or thermopulsation treatment for meibomian gland dysfunction

Cited by 21 publications

References 40 publications

Oxidative and antioxidative stress markers in dry eye disease: A systematic review and meta‐analysis

Oxidative and antioxidative stress markers in dry eye disease: A systematic review and meta‐analysis

Tailored Polymer-Based Selective Extraction of Lipid Mediators from Biological Samples

Dry eye: why artificial tears are not always the answer

Contact Info

Product

Resources

About